Urothelial Carcinoma In Situ — Trials

Urothelial Carcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: AC.TA. S.r.l.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02901548	Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder	terminated	Phase 2	17	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Jul 29, 2022	clinicaltrials
NCT03335059	Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA)	terminated	Phase 3	5	Medical Enterprises Ltd.